Pharmachem Innovations Launches as a Leading Independent Provider of Nutraceuticals Products and Solutions
Pharmachem Innovations, has launched as an independent company following its acquisition from Ashland, Inc. (NYSE: ASH) by Turnspire Capital Partners The company, headquartered in Kearny, NJ, is a leading provider of nutraceuticals products and solutions with manufacturing facilities in the US and Mexico.
Maurice Murphy has been named Executive Chairman, while Jeff Rogers joins as Interim CEO. Pharmachem aims to accelerate growth through customer partnerships and investments in new capabilities. The company produces proprietary and private-labeled products for various health applications and offers custom formulation and contract manufacturing services.
Pharmachem Innovations è stata lanciata come azienda indipendente a seguito della sua acquisizione da Ashland, Inc. (NYSE: ASH) da parte di Turnspire Capital Partners. La società, avente sede a Kearny, NJ, è un fornitore leader di prodotti e soluzioni nutraceutiche con impianti di produzione negli Stati Uniti e in Messico.
Maurice Murphy è stato nominato Presidente Esecutivo, mentre Jeff Rogers entra come CEO ad interim. Pharmachem punta ad accelerare la crescita attraverso partnership con i clienti e investimenti in nuove capacità. L'azienda produce prodotti propri e a marchio privato per varie applicazioni sanitarie e offre servizi di formulazione personalizzata e produzione in contratto.
Pharmachem Innovations ha sido lanzada como una empresa independiente tras su adquisición de Ashland, Inc. (NYSE: ASH) por Turnspire Capital Partners. La compañía, con sede en Kearny, NJ, es un proveedor líder de productos y soluciones nutracéuticas con instalaciones de fabricación en EE. UU. y México.
Maurice Murphy ha sido nombrado Presidente Ejecutivo, mientras que Jeff Rogers se une como CEO interino. Pharmachem busca acelerar el crecimiento a través de asociaciones con clientes e inversiones en nuevas capacidades. La empresa produce productos de marca propia y privada para diversas aplicaciones de salud y ofrece servicios de formulación personalizada y fabricación por contrato.
Pharmachem Innovations는 Turnspire Capital Partners에 의해 Ashland, Inc. (NYSE: ASH)로부터 인수된 독립 회사로 출범했습니다. 뉴저지주 카니에 본사를 둔 이 회사는 영양소 제품 및 솔루션의 선도적인 공급업체로, 미국과 멕시코에 제조 시설을 두고 있습니다.
모리스 머피가 집행 회장으로 임명되었고, 제프 로저스는 임시 CEO로 합류했습니다. Pharmachem은 고객 파트너십과 새로운 역량에 대한 투자를 통해 성장을 가속화하는 것을 목표로 합니다. 이 회사는 다양한 건강 애플리케이션을 위한 독점 및 개인 상표 제품을 생산하고 맞춤형 조제 및 계약 제조 서비스를 제공합니다.
Pharmachem Innovations a été lancé en tant qu'entreprise indépendante suite à son acquisition d'Ashland, Inc. (NYSE: ASH) par Turnspire Capital Partners. L'entreprise, dont le siège est situé à Kearny, NJ, est un fournisseur de premier plan de produits et solutions nutraceutiques avec des installations de fabrication aux États-Unis et au Mexique.
Maurice Murphy a été nommé Président Exécutif, tandis que Jeff Rogers rejoint l'entreprise en tant que PDG intérimaire. Pharmachem vise à accélérer la croissance grâce à des partenariats avec les clients et des investissements dans de nouvelles capacités. L'entreprise produit des produits à marque propre et des produits de marque privée pour diverses applications de santé et propose des services de formulation personnalisée et de fabrication sous contrat.
Pharmachem Innovations wurde nach der Übernahme von Ashland, Inc. (NYSE: ASH) durch Turnspire Capital Partners als unabhängiges Unternehmen gegründet. Das Unternehmen mit Sitz in Kearny, NJ, ist ein führender Anbieter von Nutraceuticals-Produkten und -Lösungen mit Produktionsstätten in den USA und Mexiko.
Maurice Murphy wurde zum Executive Chairman ernannt, während Jeff Rogers als Interims-CEO eintritt. Pharmachem zielt darauf ab, das Wachstum durch Kundenpartnerschaften und Investitionen in neue Fähigkeiten zu beschleunigen. Das Unternehmen produziert eigene und private Label-Produkte für verschiedene Gesundheitsanwendungen und bietet maßgeschneiderte Formulierungen und Vertragsproduktionsdienstleistungen an.
- Acquisition by Turnspire Capital Partners may provide resources for growth
- Experienced leadership team with Maurice Murphy as Executive Chairman and Jeff Rogers as Interim CEO
- Global presence with manufacturing facilities in the US and Mexico
- Diverse product portfolio covering various health applications
- Offers custom formulation and contract manufacturing services
- None.
The launch of Pharmachem Innovations as an independent company through a private equity acquisition is a neutral event for public market investors. While it signals potential for growth and innovation in the nutraceuticals sector, the immediate impact on publicly traded companies is The acquisition by Turnspire Capital Partners from Ashland (NYSE: ASH) may have a minor effect on Ashland's financials, but it's unlikely to be significant given Pharmachem's relative size within Ashland's portfolio. The appointment of experienced executives like Maurice Murphy and Jeff Rogers suggests a focus on operational improvements and market expansion, which could lead to increased competition in the nutraceuticals space. However, without specific financial figures or market share data, it's challenging to quantify the potential impact on industry dynamics or public market players.
The reemergence of Pharmachem as an independent entity under the name Pharmachem Innovations reflects a broader trend in the nutraceuticals industry towards specialization and agility. This move could potentially disrupt the market dynamics, especially in key areas like hydration, joint health and cardiovascular health. The company's focus on custom formulation and contract manufacturing aligns with the growing demand for personalized nutrition solutions. However, the real impact will depend on Pharmachem's ability to leverage its newfound independence and capital backing to innovate and capture market share. The nutraceuticals market is highly competitive and Pharmachem will need to differentiate itself to stand out. Investors in public nutraceutical companies should monitor how this development affects market competition and potentially influences larger industry players to refocus their strategies.
Headquartered in
Pharmachem announced that Maurice Murphy, an Operating Partner with Turnspire, has been named Executive Chairman of the Board. Mr. Murphy was most recently CEO of UPG, a former Turnspire portfolio company, where he led the company’s transformation into a customer-focused industry leader.
“I am thrilled to join a company as customer-centric and innovation-driven as Pharmachem,” said Mr. Murphy. “As an independent company with Turnspire’s support, we will be able to accelerate the Company’s growth through close partnerships with high-caliber customers and investments in new capabilities.”
Pharmachem also announced the appointment of Jeff Rogers, a seasoned executive in the ingredients space, as Interim Chief Executive Officer. Mr. Rogers was most recently President and Chief Operating Officer of Niacet, where he was responsible for leading the company’s commercial and manufacturing operations. He has also held leadership roles at Ashland, Lonza, AkzoNobel, and National Starch.
“I am excited to join the Pharmachem team and build on its rich legacy as an innovator in the nutraceuticals space,” said Mr. Rogers. “We look forward to partnering with our valued customers to develop new and creative custom formulations and proprietary products. We are excited to leverage our vast capabilities to pursue a wide array of attractive growth opportunities while continuing to provide the highest-quality service for our customers.”
In addition to Mr. Murphy and Mr. Rogers, Pharmachem will be led by members of its current management team.
Pharmachem was the original name of the Company and was used from its founding in 1972 until 2017. As Pharmachem becomes an independent company again, the team is excited to leverage its legacy name while adding “Innovations” to reflect its path forward as an agile, capabilities-driven business.
About Pharmachem Innovations
Pharmachem Innovations is a leader in the development and production of nutraceuticals ingredients, providing both proprietary nutrition ingredients and custom formulation services to nutritional product companies.
About Turnspire Capital Partners
Turnspire Capital Partners invests in high-quality businesses that have reached strategic, financial or operational inflection points and stand to benefit from our hands-on, operationally focused approach. Turnspire’s investment philosophy is predicated on creating value through operational improvements rather than through financial leverage. Turnspire strives to make each of its portfolio companies best-in-class in their respective industry niche, and then to grow the businesses through organic initiatives or strategic acquisitions. For additional information, please visit www.turnspirecap.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240903868329/en/
Mark Semer
Gasthalter & Co.
(212) 257-4170
turnspire@gasthalter.com
Source: Turnspire Capital Partners LLC
FAQ
What is Pharmachem Innovations' new status after separating from Ashland (ASH)?
Who are the key new leaders appointed at Pharmachem Innovations?
What are Pharmachem Innovations' main product offerings?
Where are Pharmachem Innovations' manufacturing facilities located?
